Phreesia Faces Class Action Lawsuit from Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 28 minutes ago
0mins
Should l Buy PHR?
Source: Globenewswire
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Phreesia, alleging violations of federal securities laws from May 8, 2025, to March 30, 2026, seeking to recover losses for investors.
- Allegations Details: The complaint claims that Phreesia failed to disclose slowing demand and diminished visibility into key revenue streams during the class period, resulting in materially false and misleading statements about the company's business operations.
- Investor Actions: Affected investors have until July 13, 2026, to request to be appointed as lead plaintiff, with the law firm operating on a contingency fee basis, thereby minimizing financial risk for investors.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman LLC is recognized for its success in recovering hundreds of millions for investors nationwide, emphasizing its expertise in securities fraud class actions and commitment to upholding market integrity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.170
Low
24.00
Averages
29.09
High
35.00
Current: 9.170
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phreesia Faces Class Action Lawsuit from Investors
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Phreesia, alleging violations of federal securities laws from May 8, 2025, to March 30, 2026, seeking to recover losses for investors.
- Allegations Details: The complaint claims that Phreesia failed to disclose slowing demand and diminished visibility into key revenue streams during the class period, resulting in materially false and misleading statements about the company's business operations.
- Investor Actions: Affected investors have until July 13, 2026, to request to be appointed as lead plaintiff, with the law firm operating on a contingency fee basis, thereby minimizing financial risk for investors.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman LLC is recognized for its success in recovering hundreds of millions for investors nationwide, emphasizing its expertise in securities fraud class actions and commitment to upholding market integrity.
See More
Phreesia Faces Securities Class Action Over Growth Misrepresentation
- Significant Stock Decline: Phreesia's shares fell approximately $3.03, a 27% drop, after the company revised its fiscal 2027 revenue outlook from $545-$559 million to $510-$520 million, directly impacting investor confidence and triggering a class action lawsuit.
- Misrepresentation of Acquisition Promises: The lawsuit alleges that Phreesia misled investors regarding the AccessOne acquisition, claiming it would contribute about 6.5% to fiscal 2027 total revenue, while actual market demand was weakening, leading to a substantial downward revision of growth expectations.
- Unraveling of Growth Narrative: On March 30, 2026, Phreesia disclosed that pharmaceutical manufacturers were committing significantly lower spending levels for the second half of fiscal 2027 than anticipated, resulting in a reduction of projected growth from 14-16% to approximately 6-8%, indicating a misjudgment by management regarding market conditions.
- Investor Rights at Stake: The lawsuit emphasizes that investors deserve transparency about material risks that could affect their investments, as Phreesia's failure to disclose potential market weaknesses while promoting growth drivers has led to significant financial losses for shareholders.
See More
Phreesia Faces Class Action Lawsuit Risks
- Class Action Notification: The Portnoy Law Firm advises Phreesia investors of a class action for those who purchased securities between May 8, 2025, and March 30, 2026, with a deadline for lead plaintiff motions set for July 13, 2026, indicating significant legal risks that could undermine shareholder confidence.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia lowered its fiscal year 2027 revenue outlook from $545 million to $559 million down to a range of $510 million to $520 million, reflecting reduced visibility into future spending commitments from pharmaceutical manufacturers, which may weaken investor confidence in the company's growth prospects.
- Severe Market Reaction: Following the revenue outlook downgrade, Phreesia's stock price plummeted from $11.41 per share to $8.38 per share, a decline of approximately 27%, indicating market concerns regarding the company's financial health and potential impacts on its financing capabilities and market position.
- Decreased Client Spending: The company disclosed that Network Solutions clients were committing lower spending levels for the second half of fiscal year 2027 than anticipated, along with increased variability in revenue forecasting, suggesting greater uncertainty in the competitive landscape that could affect the company's long-term strategic planning.
See More
Phreesia Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Phreesia, alleging that the company and certain officers may have engaged in securities fraud and other unlawful business practices, which could expose the company to significant legal risks.
- Stock Price Plunge: Following the announcement on March 30, 2026, of drastically reduced revenue growth projections for fiscal year 2027, Phreesia's stock price fell by 26.56% to close at $8.38 per share, indicating a negative market sentiment regarding the company's future.
- Reasons for Revenue Downgrade: Phreesia attributed the revenue shortfall to macroeconomic factors, including “worsening visibility” and weakened pharmaceutical marketing commitments within its Network Solutions segment, highlighting the company's vulnerability in the current market environment.
- Investor Action Deadline: Investors are advised to apply to be appointed as Lead Plaintiff in the class action by July 13, 2026, suggesting that the ongoing legal challenges may impact the company's future investment appeal.
See More
Phreesia Shareholder Alert: Class Action Notice Issued
- Class Action Notice: The Gross Law Firm has issued a notice to Phreesia shareholders, encouraging those who purchased shares between May 8, 2025, and March 30, 2026, to contact the firm regarding potential lead plaintiff status, indicating significant legal risks for the company.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, primarily due to weakened pharmaceutical marketing commitments and macroeconomic factors, highlighting a slowdown in demand across key revenue streams.
- Stock Price Decline: Following the revenue guidance cut, Phreesia's stock price plummeted from $11.41 per share on March 30, 2025, to $8.38 per share on March 31, 2026, representing a 27% decline, reflecting market pessimism regarding the company's future prospects.
- Shareholder Action Recommended: Shareholders are advised to register for the class action by July 13, 2026, and will receive real-time updates on the case's progress, underscoring the importance of legal support and protection of shareholder rights.
See More
Phreesia Faces Class Action Lawsuit Risks
- Lawsuit Background: Robbins LLP has alerted investors that a class action has been filed on behalf of shareholders who purchased Phreesia (NYSE: PHR) stock between May 8, 2025, and March 30, 2026, alleging that the company misled investors regarding the sustainability of growth in its Network Solutions business, potentially leading to significant investor losses.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia announced a reduction in its fiscal 2027 revenue outlook from a range of $545 million to $559 million down to $510 million to $520 million, indicating a decrease in visibility into future spending commitments and jeopardizing its long-term growth prospects.
- Stock Price Plunge: Following the revenue outlook downgrade, Phreesia's stock price fell from $11.41 per share on March 30, 2026, to $8.38 per share on March 31, 2026, representing a decline of approximately 27%, reflecting strong market concerns about the company's future performance.
- Investor Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by July 13, 2026, highlighting the importance of corporate governance and executive accountability, as investors seek to recover losses through this litigation.
See More
Phreesia Faces Class Action Lawsuit from Investors
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Phreesia, alleging violations of federal securities laws from May 8, 2025, to March 30, 2026, seeking to recover losses for investors.
- Allegations Details: The complaint claims that Phreesia failed to disclose slowing demand and diminished visibility into key revenue streams during the class period, resulting in materially false and misleading statements about the company's business operations.
- Investor Actions: Affected investors have until July 13, 2026, to request to be appointed as lead plaintiff, with the law firm operating on a contingency fee basis, thereby minimizing financial risk for investors.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman LLC is recognized for its success in recovering hundreds of millions for investors nationwide, emphasizing its expertise in securities fraud class actions and commitment to upholding market integrity.
See More
Phreesia Faces Securities Class Action Over Growth Misrepresentation
- Significant Stock Decline: Phreesia's shares fell approximately $3.03, a 27% drop, after the company revised its fiscal 2027 revenue outlook from $545-$559 million to $510-$520 million, directly impacting investor confidence and triggering a class action lawsuit.
- Misrepresentation of Acquisition Promises: The lawsuit alleges that Phreesia misled investors regarding the AccessOne acquisition, claiming it would contribute about 6.5% to fiscal 2027 total revenue, while actual market demand was weakening, leading to a substantial downward revision of growth expectations.
- Unraveling of Growth Narrative: On March 30, 2026, Phreesia disclosed that pharmaceutical manufacturers were committing significantly lower spending levels for the second half of fiscal 2027 than anticipated, resulting in a reduction of projected growth from 14-16% to approximately 6-8%, indicating a misjudgment by management regarding market conditions.
- Investor Rights at Stake: The lawsuit emphasizes that investors deserve transparency about material risks that could affect their investments, as Phreesia's failure to disclose potential market weaknesses while promoting growth drivers has led to significant financial losses for shareholders.
See More
Phreesia Faces Class Action Lawsuit Risks
- Class Action Notification: The Portnoy Law Firm advises Phreesia investors of a class action for those who purchased securities between May 8, 2025, and March 30, 2026, with a deadline for lead plaintiff motions set for July 13, 2026, indicating significant legal risks that could undermine shareholder confidence.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia lowered its fiscal year 2027 revenue outlook from $545 million to $559 million down to a range of $510 million to $520 million, reflecting reduced visibility into future spending commitments from pharmaceutical manufacturers, which may weaken investor confidence in the company's growth prospects.
- Severe Market Reaction: Following the revenue outlook downgrade, Phreesia's stock price plummeted from $11.41 per share to $8.38 per share, a decline of approximately 27%, indicating market concerns regarding the company's financial health and potential impacts on its financing capabilities and market position.
- Decreased Client Spending: The company disclosed that Network Solutions clients were committing lower spending levels for the second half of fiscal year 2027 than anticipated, along with increased variability in revenue forecasting, suggesting greater uncertainty in the competitive landscape that could affect the company's long-term strategic planning.
See More
Phreesia Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Phreesia, alleging that the company and certain officers may have engaged in securities fraud and other unlawful business practices, which could expose the company to significant legal risks.
- Stock Price Plunge: Following the announcement on March 30, 2026, of drastically reduced revenue growth projections for fiscal year 2027, Phreesia's stock price fell by 26.56% to close at $8.38 per share, indicating a negative market sentiment regarding the company's future.
- Reasons for Revenue Downgrade: Phreesia attributed the revenue shortfall to macroeconomic factors, including “worsening visibility” and weakened pharmaceutical marketing commitments within its Network Solutions segment, highlighting the company's vulnerability in the current market environment.
- Investor Action Deadline: Investors are advised to apply to be appointed as Lead Plaintiff in the class action by July 13, 2026, suggesting that the ongoing legal challenges may impact the company's future investment appeal.
See More
Phreesia Shareholder Alert: Class Action Notice Issued
- Class Action Notice: The Gross Law Firm has issued a notice to Phreesia shareholders, encouraging those who purchased shares between May 8, 2025, and March 30, 2026, to contact the firm regarding potential lead plaintiff status, indicating significant legal risks for the company.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, primarily due to weakened pharmaceutical marketing commitments and macroeconomic factors, highlighting a slowdown in demand across key revenue streams.
- Stock Price Decline: Following the revenue guidance cut, Phreesia's stock price plummeted from $11.41 per share on March 30, 2025, to $8.38 per share on March 31, 2026, representing a 27% decline, reflecting market pessimism regarding the company's future prospects.
- Shareholder Action Recommended: Shareholders are advised to register for the class action by July 13, 2026, and will receive real-time updates on the case's progress, underscoring the importance of legal support and protection of shareholder rights.
See More
Phreesia Faces Class Action Lawsuit Risks
- Lawsuit Background: Robbins LLP has alerted investors that a class action has been filed on behalf of shareholders who purchased Phreesia (NYSE: PHR) stock between May 8, 2025, and March 30, 2026, alleging that the company misled investors regarding the sustainability of growth in its Network Solutions business, potentially leading to significant investor losses.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia announced a reduction in its fiscal 2027 revenue outlook from a range of $545 million to $559 million down to $510 million to $520 million, indicating a decrease in visibility into future spending commitments and jeopardizing its long-term growth prospects.
- Stock Price Plunge: Following the revenue outlook downgrade, Phreesia's stock price fell from $11.41 per share on March 30, 2026, to $8.38 per share on March 31, 2026, representing a decline of approximately 27%, reflecting strong market concerns about the company's future performance.
- Investor Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by July 13, 2026, highlighting the importance of corporate governance and executive accountability, as investors seek to recover losses through this litigation.
See More
